These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27658385)

  • 1. MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort.
    Cohan S; Chen C; Baraban E; Stuchiner T; Grote L
    BMC Neurol; 2016 Sep; 16(1):184. PubMed ID: 27658385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
    Romeo M; Martinelli-Boneschi F; Rodegher M; Esposito F; Martinelli V; Comi G;
    Eur J Neurol; 2013 Jul; 20(7):1060-7. PubMed ID: 23425504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No].
    Edan G
    Rev Neurol (Paris); 2013 Nov; 169(11):864-8. PubMed ID: 24125462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
    Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
    J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endovascular treatment of chronic cerebrospinal venous insufficiency in multiple sclerosis: a retrospective study.
    Alroughani R; Lamdhade S; Thussu A
    Int J Neurosci; 2013 May; 123(5):324-8. PubMed ID: 23301864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.